Microvascular Coronary Disease In Women: Impact Of Ranolazine
Status:
Completed
Trial end date:
2009-12-01
Target enrollment:
Participant gender:
Summary
1. To evaluate the impact of ranolazine extended-release tablets in women with
subendocardial ischemia due to microvascular endothelial dysfunction on myocardial
ischemia (Cardiac Magnetic Resonance (CMR) extent, severity.
2. To evaluate the impact of ranolazine extended-release tablets in women with
subendocardial ischemia due to microvascular endothelial dysfunction on the outcomes of
angina (Seattle Angina Questionnaire (SAQ), WISE angina frequency, Duke Activity Status
Inventory(DASI) and SF-36).